NCGC National Clinical Guideline Centre

Crohn's disease

Appendix Q

Clinical Guideline <...>

Sift audit

10 October 2012

NICE's original guidance on Crohn's disease: management in adults, children and young people was published in October 2012; it was partially updated in May 2016 when a new recommendation on inducing remission was added. It has now undergone a further partial update published in May 2019. The full, current recommendations can be found on the NICE website.

This document preserves evidence for areas of the guideline that have not been updated in 2019. Black shading indicates text from 2012 replaced by the 2019 update.

Commissioned by the National Institute for Health and Clinical Excellence

Royal College of Physicians
Setting higher medical standards
Royal College of Nursing
RCS ADVANCING SURGICAL STANDARDS
RC GP Royal College of General Practitioners
NHS Evidence accredited provider
NHS Evidence - provided by NICE
www.evidence.nhs.uk

Published by the National Clinical Guideline Centre at
The Royal College of Physicians, 11 St Andrews Place, Regents Park, London, NW1 4BT

First published 10 October, 2012

Contents

1 Sift audits

1.1 Conventional glucocorticosteroid treatment for inducing remission

In individuals diagnosed with Crohn's disease what is the clinical and cost effectiveness of conventional glucocorticosteroid treatment for induction of remission

- compared with placebo?
- compared with 5-aminosalicylate (5-ASA) treatment?
- *plus* 5-ASA treatment compared with placebo?
- compared with azathioprine or mercaptopurine (AZA/MP)?
- *plus* azathioprine or mercaptopurine (AZA/MP) compared with conventional glucocorticosteroid treatment *plus* placebo?
- compared with methotrexate?
- *plus* methotrexate compared with conventional glucocorticosteroid treatment *plus* placebo?



1.2 Budesonide for induction of remission

In individuals diagnosed with Crohn's disease what is the clinical and cost effectiveness of low dose and high dose budesonide for induction of remission compared with

- placebo?
- conventional glucocorticosteroid treatment?
- 5-aminosalicylate (5-ASA) treatment?
- azathioprine or mercaptopurine (AZA/MP)?
- methotrexate?



1.3 5-ASA treatment for induction of remission

In individuals diagnosed with Crohn's disease what is the clinical and cost effectiveness of 5-aminosalicylate (5-ASA) treatment for induction of remission compared with

- placebo?
- azathioprine or mercaptopurine (AZA/MP)?
- methotrexate?

1.4 Immunosuppressive (AZA/MP; methotrexate) therapy for induction of remission

In individuals diagnosed with Crohn's disease what is the clinical and cost effectiveness of azathioprine or mercaptopurine (AZA/MP) for induction of remission compared with

- placebo?
- methotrexate?

In individuals diagnosed with Crohn's disease what is the incidence of serious adverse events for the following subgroups:

- normal blood TPMT activity, on a standard dose of azathioprine
- low blood TPMT activity, on a low dose of azathioprine
- blood TPMT is unknown, on a standard dose of azathioprine?

In individuals diagnosed with Crohn's disease what is the clinical and cost effectiveness of methotrexate for induction of remission

- compared with placebo?
- *plus* conventional glucocorticosteroid treatment compared with placebo *plus* conventional glucocorticosteroid treatment?


Titles and abstracts identified
n = 5014 5-ASA, AZA/MP
n= 278 TPMT
Full copies retrieved and assessed for eligibility
n = 92
Excluded n = 5200
Not relevant design, intervention, comparison and specified outcomes
Publications included in the review
n = 15 efficacy
n = 13 safety
n = 5 TPMT
Excluded
n = 59 (see exclusion list)

1.5 Conventional glucocorticosteroid treatment for maintaining remission

In individuals diagnosed with Crohn's disease what is the clinical and cost effectiveness of conventional glucocorticosteroid treatment for maintenance of remission for 12 months or longer

- compared with placebo?
- compared with 5-aminosalicylate (5-ASA) treatment?
- *plus* 5-ASA treatment with conventional glucocorticosteroid *plus* placebo ?
- compared with azathioprine or mercaptopurine (AZA/MP)?
- *plus* azathioprine or mercaptopurine compared with conventional glucocorticosteroid treatment *plus* placebo?
- methotrexate?



1.6 Budesonide for maintaining remission

In individuals diagnosed with Crohn's disease what is the clinical and cost effectiveness of low dose and high dose budesonide for maintenance of remission for 12 months or longer compared with

- placebo?
- conventional glucocorticosteroid treatment?
- 5-aminosalicylate (5-ASA) treatment?
- azathioprine or mercaptopurine (AZA/MP)?
- methotrexate?



1.7 5-ASA treatment for maintaining remission

In individuals diagnosed with Crohn's disease what is the clinical and cost effectiveness of 5-aminosalicylate (5-ASA) treatment for maintenance of remission compared with

- placebo?
- azathioprine or mercaptopurine (AZA/MP)?
- methotrexate?



1.8 Azathioprine/mercaptopurine for maintaining remission

In individuals diagnosed with Crohn's disease what is the clinical and cost effectiveness of azathioprine or mercaptopurine (AZA/MP) for maintenance of remission for 12 months or longer

- compared with placebo?
- compared with methotrexate?
- *plus* conventional glucocorticosteroid or 5-ASA treatment compared with placebo *plus* conventional glucocorticosteroid or 5-ASA treatment?



1.9 Methotrexate for maintaining remission

In individuals diagnosed with Crohn's disease what is the clinical and cost effectiveness of methotrexate for maintenance of remission for 12 months or longer

- compared with placebo?
- *plus* conventional glucocorticosteroid treatment compared with placebo *plus* conventional glucocorticosteroid treatment?



1.10 Post-surgical maintenance of remission

Please note that evidence on treatments for post-surgical maintenance of remission in Crohn's disease was reviewed in 2019. The updated evidence review and full current recommendations can be found on the NICE website.

- conventional glucocorticosteroid treatment
- budesonide
- 5-aminosalicylate treatment
- azathioprine
- mercaptopurine
- methotrexate
- metronidazole or
- combinations thereof
- or nutritional treatment

compared with

- placebo
- no treatment ?



1.11 Enteral nutrition for the induction of remission

In adults and children diagnosed with Crohn's disease what is the clinical and cost effectiveness of enteral nutrition (elemental, semi-elemental and polymeric) as a sole source of nutrition for induction of remission compared with

- usual diet
- conventional glucocorticosteroid treatment
- budesonide
- a combination of conventional glucocorticosteroid treatment *plus* 5-ASA treatment
- a combination of conventional glucocorticosteroid treatment *plus* azathioprine or mercaptopurine
- a combination of conventional glucocorticosteroid treatment *plus* methotrexate?

In adults and children diagnosed with Crohn's disease what is the clinical and cost effectiveness for induction of remission of enteral nutrition (elemental, semi-elemental and polymeric) plus medical therapy versus usual diet?



1.12 Enteral nutrition for the maintenance of remission

What is the clinical and cost effectiveness of enteral nutrition (elemental, semi-elemental and polymeric) for maintenance of remission compared with

- usual diet?
- medical treatment?
- conventional glucocorticosteroid treatment?
- budesonide?
- 5-ASA treatment?
- azathioprine or mercaptopurine?
- methotrexate?

What is the clinical and cost effectiveness of enteral nutrition (elemental, semi-elemental and polymeric) for maintenance of remission in combination with

- conventional glucocorticosteroid treatment
- budesonide
- 5-ASA treatment
- azathioprine or mercaptopurine
- methotrexate

compared with any of the above?



1.13 Surgery versus medical management for disease limited to the distal ileum

In individuals diagnosed with Crohn's disease limited to the distal ileum, what is the clinical and cost-effectiveness of surgical resection for induction and maintenance of remission compared with medical or nutritional treatment?



1.14 Treatment of stricture in Crohn's disease: surgical management versus balloon dilation of stricture

In individuals diagnosed with Crohn's disease what is the clinical and cost effectiveness of surgical treatment of stricture compared with

- balloon dilation?
- balloon dilation plus intralesional glucocorticosteroid injections?
- conservative management?



1.15 Monitoring for osteopenia

In children with Crohn's disease what is the risk of fracture?



1.16 Monitoring for early relapse

Does predicting early relapse through monitoring

- Unintended weight loss,
- CRP,
- ESR,
- MRI,
- Calprotectin,
- Colonoscopy/capsule endoscopy or
- Growth in children

compared to standard care, improve patient outcomes (quality of life, future surgery, hospitalization)?



1.17 Patient information and support

- What are the primary information needs of adults with Crohn's disease in the UK?
- What are the primary information needs of children and young people with Crohn's disease in the UK?



1.18 Reruns

All above searches were updated on 13 March 2012, and the following studies were identified: